<p>Lyell Immunopharma（納斯達克代碼：LYEL - 獲取免費報告）預計將在 2026 年 5 月 12 日星期二市場開盤前公佈其 2026 年第一季度的業績。分析師預計該公司將公佈每股收益為（$2.3650）和該季度收入為$0.0060 百萬。投資者可以在公司即將發佈的 2026 年第一季度財報頁面找到電話會議的詳細信息，最新的電話會議安排在 2026 年 5 月 13 日星期三東部時間下午 4:00。</p>
<p>獲取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
<p>Lyell Immunopharma（納斯達克代碼：LYEL - 獲取免費報告）最近一次公佈季度財報是在 3 月 12 日星期四。該公司報告的季度每股收益為（$7.68），低於分析師共識預期的（$2.15），差距為（$5.53）。該季度的收入為$0.01 百萬，而分析師預期為$0.02 百萬。Lyell Immunopharma 的淨利潤率為負 762,355.56%，股本回報率為負 90.52%。平均而言，分析師預計 Lyell Immunopharma 在當前財政年度的每股收益為$-10，在下一個財政年度的每股收益為$-12。</p>
<h2>Lyell Immunopharma 股票表現</h2>
<p>在週二的交易時段，LYEL 的股價下跌$0.35，達到$20.37。該公司交易了 25,050 股，較其平均交易量 96,931 股有所減少。該股票的 50 日移動平均線為$22.30，200 日移動平均線為$23.45。該股票的市值為$4.7523 億，市盈率為-1.25，貝塔值為-0.05。Lyell Immunopharma 的 1 年最低價為$7.65，最高價為$45.00。</p>
<h2>分析師評級調整</h2>
<p>一些研究分析師最近對 LYEL 股票發表了評論。華爾街 Zen 在週六的研究報告中將 Lyell Immunopharma 的股票評級從 “持有” 下調至 “賣出”。Zacks Research 在 4 月 7 日星期二的研究報告中將 Lyell Immunopharma 的股票評級從 “持有” 下調至 “強烈賣出”。Citizens Jmp 在 3 月 9 日星期一的研究報告中開始覆蓋 Lyell Immunopharma 的股票。他們給予該股票 “市場表現優於大盤” 的評級，目標價為$34.00。Needham &amp; Company LLC 在 4 月 10 日星期五的研究報告中開始覆蓋 Lyell Immunopharma 的股票。他們給予該股票 “買入” 評級，目標價為$44.00。最後，Robert W. Baird 在週四的研究報告中為 Lyell Immunopharma 的股票設定了$49.00 的目標價，並給予公司 “表現優於大盤” 的評級。一位研究分析師給予該股票 “強烈買入” 評級，三位給予 “買入” 評級，兩位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為$43.00。</p>
<p><strong>閲讀我們關於 Lyell Immunopharma 的最新報告</strong></p>
<h2>Lyell Immunopharma 的內部交易活動</h2>
<p>在相關消息中，內部人士 Gary K. Lee 在 2 月 11 日星期三出售了 1,671 股公司的股票。股票以平均價格$23.39 出售，總價值為$39,084.69。出售後，內部人士持有公司的 16,938 股股票，價值為$396,179.82。此次交易使其持股減少了 8.98%。該交易在與 SEC 的法律文件中披露，相關信息可通過此超鏈接獲取。此外，首席執行官 Lynn Seely 在 2 月 11 日星期三出售了 7,455 股公司的股票。股票以平均價格$23.39 出售，總交易額為$174,372.45。出售完成後，首席執行官直接持有公司的 74,266 股股票，價值約為$1,737,081.74。此次交易使其持股減少了 9.12%。該出售的 SEC 文件提供了更多信息。內部人士在上個季度共出售了 11,310 股公司股票，價值為$264,285。公司內部人士持有 6.20% 的股票。</p>
<h2>Lyell Immunopharma 的機構交易</h2>
<p>大型投資者最近增加或減少了在公司的持股。ExodusPoint Capital Management LP 在第四季度購買了 Lyell Immunopharma 的新股份，價值約為$262,000。Marshall Wace LLP 在第二季度購買了 Lyell Immunopharma 的新股份，價值約為$94,000。Jane Street Group LLC 在第四季度購買了 Lyell Immunopharma 的新股份，價值約為$382,000。巴克萊銀行在第四季度將其在 Lyell Immunopharma 的持股增加了 1,239.5%。巴克萊銀行現在持有該公司 15,967 股股票，價值$491,000，此前在上個季度又購買了 14,775 股。最後，Bridgeway Capital Management LLC 在第二季度購買了 Lyell Immunopharma 的新股份，價值約為$159,000。66.05% 的股票由機構投資者持有。</p>
<h2>Lyell Immunopharma 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Lyell Immunopharma 是一家臨牀階段的生物技術公司，專注於開發下一代 T 細胞療法用於癌症治療。該公司利用一個結合了細胞療法、基因編輯和分子發現的專有平台，旨在克服治療實體腫瘤的關鍵障礙。公司的方法集中在工程化 T 細胞，以增強其持久性、功能性和對免疫抑制腫瘤微環境的抵抗力。</p>
<p>公司的產品管線包括多個自體 T 細胞項目，旨在針對黑色素瘤、卵巢癌和胰腺癌等實體惡性腫瘤中的腫瘤相關抗原。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Lyell Immunopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Lyell Immunopharma 嗎？</h2>
<p>在考慮 Lyell Immunopharma 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Lyell Immunopharma 並不在名單上。</p>
<p>雖然 Lyell Immunopharma 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LYEL

<p>Lyell Immunopharma（納斯達克代碼：LYEL）計劃於 5 月 12 日發佈 2026 年第一季度財報，分析師預測每股虧損為 2.3650 美元，收入為 0.0060 百萬美元。該公司此前報告 2025 年第一季度每股虧損 7.68 美元，未能達到預期。LYEL 股票最近交易價格為 20.37 美元，下跌 0.35 美元，市值為 4.7523 億美元。分析師對該股票的評級不一，普遍評級為 “適度買入”，目標價格為 43.00 美元。內部交易活動近期出現了顯著的股票出售</p>

<p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($2.3650) per share and revenue of $0.0060 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Lyell Immunopharma（納斯達克代碼：LYEL - 獲取免費報告）預計將在 2026 年 5 月 12 日星期二市場開盤前公佈其 2026 年第一季度的業績。分析師預計該公司將公佈每股收益為（$2.3650）和該季度收入為$0.0060 百萬。投資者可以在公司即將發佈的 2026 年第一季度財報頁面找到電話會議的詳細信息，最新的電話會議安排在 2026 年 5 月 13 日星期三東部時間下午 4:00。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($7.68) EPS for the quarter, missing analysts' consensus estimates of ($2.15) by ($5.53). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Lyell Immunopharma had a negative net margin of 762,355.56% and a negative return on equity of 90.52%. On average, analysts expect Lyell Immunopharma to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（納斯達克代碼：LYEL - 獲取免費報告）最近一次公佈季度財報是在 3 月 12 日星期四。該公司報告的季度每股收益為（$7.68），低於分析師共識預期的（$2.15），差距為（$5.53）。該季度的收入為$0.01 百萬，而分析師預期為$0.02 百萬。Lyell Immunopharma 的淨利潤率為負 762,355.56%，股本回報率為負 90.52%。平均而言，分析師預計 Lyell Immunopharma 在當前財政年度的每股收益為$-10，在下一個財政年度的每股收益為$-12。</p>
</div><h2>Lyell Immunopharma Stock Performance</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 股票表現</h2>
</div><p>Shares of LYEL traded down $0.35 during trading hours on Tuesday, reaching $20.37. 25,050 shares of the company traded hands, compared to its average volume of 96,931. The stock's fifty day moving average is $22.30 and its 200 day moving average is $23.45. The stock has a market cap of $475.23 million, a P/E ratio of -1.25 and a beta of -0.05. Lyell Immunopharma has a 1-year low of $7.65 and a 1-year high of $45.00.</p>
<div class="lb-trans"><p>在週二的交易時段，LYEL 的股價下跌$0.35，達到$20.37。該公司交易了 25,050 股，較其平均交易量 96,931 股有所減少。該股票的 50 日移動平均線為$22.30，200 日移動平均線為$23.45。該股票的市值為$4.7523 億，市盈率為-1.25，貝塔值為-0.05。Lyell Immunopharma 的 1 年最低價為$7.65，最高價為$45.00。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of research analysts have recently commented on LYEL shares. Wall Street Zen lowered shares of Lyell Immunopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. Zacks Research lowered shares of Lyell Immunopharma from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Tuesday, April 7th. Citizens Jmp began coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They issued a &#34;market outperform&#34; rating and a $34.00 target price on the stock. Needham &amp; Company LLC began coverage on shares of Lyell Immunopharma in a research note on Friday, April 10th. They issued a &#34;buy&#34; rating and a $44.00 target price on the stock. Finally, Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the company an &#34;outperform&#34; rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $43.00.</p>
<div class="lb-trans"><p>一些研究分析師最近對 LYEL 股票發表了評論。華爾街 Zen 在週六的研究報告中將 Lyell Immunopharma 的股票評級從 “持有” 下調至 “賣出”。Zacks Research 在 4 月 7 日星期二的研究報告中將 Lyell Immunopharma 的股票評級從 “持有” 下調至 “強烈賣出”。Citizens Jmp 在 3 月 9 日星期一的研究報告中開始覆蓋 Lyell Immunopharma 的股票。他們給予該股票 “市場表現優於大盤” 的評級，目標價為$34.00。Needham &amp; Company LLC 在 4 月 10 日星期五的研究報告中開始覆蓋 Lyell Immunopharma 的股票。他們給予該股票 “買入” 評級，目標價為$44.00。最後，Robert W. Baird 在週四的研究報告中為 Lyell Immunopharma 的股票設定了$49.00 的目標價，並給予公司 “表現優於大盤” 的評級。一位研究分析師給予該股票 “強烈買入” 評級，三位給予 “買入” 評級，兩位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為$43.00。</p>
</div><p><strong>Read Our Latest Report on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Lyell Immunopharma 的最新報告</strong></p>
</div><h2>Insider Activity at Lyell Immunopharma</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 的內部交易活動</h2>
</div><p>In related news, insider Gary K. Lee sold 1,671 shares of the company's stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $39,084.69. Following the sale, the insider owned 16,938 shares of the company's stock, valued at $396,179.82. The trade was a 8.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Lynn Seely sold 7,455 shares of the company's stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $174,372.45. Following the completion of the sale, the chief executive officer directly owned 74,266 shares in the company, valued at approximately $1,737,081.74. The trade was a 9.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,310 shares of company stock valued at $264,285 over the last quarter. 6.20% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Gary K. Lee 在 2 月 11 日星期三出售了 1,671 股公司的股票。股票以平均價格$23.39 出售，總價值為$39,084.69。出售後，內部人士持有公司的 16,938 股股票，價值為$396,179.82。此次交易使其持股減少了 8.98%。該交易在與 SEC 的法律文件中披露，相關信息可通過此超鏈接獲取。此外，首席執行官 Lynn Seely 在 2 月 11 日星期三出售了 7,455 股公司的股票。股票以平均價格$23.39 出售，總交易額為$174,372.45。出售完成後，首席執行官直接持有公司的 74,266 股股票，價值約為$1,737,081.74。此次交易使其持股減少了 9.12%。該出售的 SEC 文件提供了更多信息。內部人士在上個季度共出售了 11,310 股公司股票，價值為$264,285。公司內部人士持有 6.20% 的股票。</p>
</div><h2>Institutional Trading of Lyell Immunopharma</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 的機構交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. ExodusPoint Capital Management LP bought a new stake in Lyell Immunopharma during the fourth quarter worth about $262,000. Marshall Wace LLP bought a new stake in Lyell Immunopharma during the second quarter worth about $94,000. Jane Street Group LLC bought a new stake in Lyell Immunopharma during the fourth quarter worth about $382,000. Barclays PLC grew its stake in Lyell Immunopharma by 1,239.5% during the fourth quarter. Barclays PLC now owns 15,967 shares of the company's stock worth $491,000 after buying an additional 14,775 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in Lyell Immunopharma during the second quarter worth about $159,000. 66.05% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了在公司的持股。ExodusPoint Capital Management LP 在第四季度購買了 Lyell Immunopharma 的新股份，價值約為$262,000。Marshall Wace LLP 在第二季度購買了 Lyell Immunopharma 的新股份，價值約為$94,000。Jane Street Group LLC 在第四季度購買了 Lyell Immunopharma 的新股份，價值約為$382,000。巴克萊銀行在第四季度將其在 Lyell Immunopharma 的持股增加了 1,239.5%。巴克萊銀行現在持有該公司 15,967 股股票，價值$491,000，此前在上個季度又購買了 14,775 股。最後，Bridgeway Capital Management LLC 在第二季度購買了 Lyell Immunopharma 的新股份，價值約為$159,000。66.05% 的股票由機構投資者持有。</p>
</div><h2>Lyell Immunopharma Company Profile</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.</p>
<div class="lb-trans"><p>Lyell Immunopharma 是一家臨牀階段的生物技術公司，專注於開發下一代 T 細胞療法用於癌症治療。該公司利用一個結合了細胞療法、基因編輯和分子發現的專有平台，旨在克服治療實體腫瘤的關鍵障礙。公司的方法集中在工程化 T 細胞，以增強其持久性、功能性和對免疫抑制腫瘤微環境的抵抗力。</p>
</div><p>The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.</p>
<div class="lb-trans"><p>公司的產品管線包括多個自體 T 細胞項目，旨在針對黑色素瘤、卵巢癌和胰腺癌等實體惡性腫瘤中的腫瘤相關抗原。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Lyell Immunopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LYEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Lyell Immunopharma 嗎？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Lyell Immunopharma 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Lyell Immunopharma 並不在名單上。</p>
</div><p>While Lyell Immunopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Lyell Immunopharma 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lyell Immunopharma (LYEL) 將在週二公佈季度收益